Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Apr 10;94(7):976-81.
doi: 10.1038/sj.bjc.6603053.

Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study

G Klautke  1 , U Küchenmeister, T Foitzik, K Ludwig, F Prall, E Klar, R Fietkau
Affiliations
Clinical Trial

Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study

G Klautke et al. Br J Cancer. .

Abstract

The aim of this study was to investigate the efficacy and safety of chemoradiation using capecitabine and irinotecan as neoadjuvant therapy for patients with rectal cancer. Conventional radiation was given at daily fractions of 1.8 Gy on 5 days a week for a total dose of 55.8 (50.4 + 5.4) Gy. Concurrently, irinotecan 40 mg m(-2) once weekly and capecitabine continuously at dose levels of 500, 650, 750 and 825 mg m(-2) twice daily were administered. Surgery was performed 4-6 weeks following completion of chemoradiation. A total of 28 patients (3 UICC II, 25 UICC III) were enrolled and all received treatment. Dose-limiting toxicity was diarrhoea grade IV and hand-foot syndrome at the 825 mg m(-2) dose level. The maximum tolerated dose of capecitabine was 750 mg m(-2). Diarrhoea was the most common toxicity: grade III in nine patients. Two patients died, one due to pneumonia and one due to sudden cardiac death. A complete response and only microfocal residual tumour disease was achieved in four and three patients (27%). In all, 25 of 28 patients undergoing surgery, 24 (96%) had R0 resection. Preoperative chemoradiation based on continuous daily capecitabine and weekly irinotecan appears to tolerated and effective in patients with rectal cancer.

PubMed Disclaimer

Comment in

References

    1. Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S (2005) A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 16: 1140–1146 - PubMed
    1. Becerra CR, Cho L, Gregoreyk S, Simmang C, Frenkel EP, Verma UN (2005) A Phase I study with irinotecan, capecitabine and radiation therapy for patients with locally advanced or metastatic rectal cancer. Proc Am Soc Clin Oncol (Abstr 212)
    1. Boothmann DA, Trask DK, Pardee AB (1987) Inhibition of potential lethal damage repair in human tumor cells by lapachone, an activator of topoisomerase I. Cancer Res 49: 605–612 - PubMed
    1. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA (1993) Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum (II)-sensitive and - resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int J Cancer 53: 118–123 - PubMed
    1. Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Marks G (1994) Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 30: 169–175 - PubMed

Publication types

MeSH terms